Active — Not RecruitingPhase 2

A Study of Mosliciguat in PH-ILD

United States135 participantsStarted 2024-10-29

Plain-language summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Idiopathic interstitial pneumonia (IIP)
✓. Chronic hypersensitivity pneumonitis
✓. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted

What they're measuring

Change from Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)

Timeframe: Baseline, Week 16

Trial details

NCT IDNCT06635850

SponsorPulmovant, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Pulmonary Hypertension trials